Mirum Pharmaceuticals公司公布的研究数据显示，其核心候选药物volixibat的安全性特征与回肠胆汁酸转运蛋白（IBAT）抑制机制高度吻合。临床观察发现，该药物引发的不良反应主要集中于胃肠道范畴，同时伴有肝脏生化参数的可逆性升高。
值得注意的是，这类安全性表现完全符合IBAT抑制剂类药物已知的作用机理预期。研究人员强调，胃肠道反应与肝酶指标变化均属可控范围，为后续临床开发提供了重要安全性依据。
Mirum Pharmaceuticals公司公布的研究数据显示，其核心候选药物volixibat的安全性特征与回肠胆汁酸转运蛋白（IBAT）抑制机制高度吻合。临床观察发现，该药物引发的不良反应主要集中于胃肠道范畴，同时伴有肝脏生化参数的可逆性升高。
值得注意的是，这类安全性表现完全符合IBAT抑制剂类药物已知的作用机理预期。研究人员强调，胃肠道反应与肝酶指标变化均属可控范围，为后续临床开发提供了重要安全性依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.